Dabur India has closed its trading window for dealing in the company's securities from July 1, 2026, to July 31, 2026. The closure is effective from Wednesday, July 1, 2026, to Friday, July 31, 2026, inclusive of both dates. This action is taken to comply with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading.

The restriction applies to all designated persons and is intended to prevent insider trading during periods when unpublished price-sensitive information may be prevalent. The intimation was submitted to the stock exchanges by Ashok Kumar Jain, Group Company Secretary and Chief Compliance Officer of Dabur India Limited.

Regulatory Compliance

The trading window closure is a standard regulatory requirement mandated by SEBI to ensure market integrity and protect investor interests. The company strictly adheres to these regulations to maintain transparency in its operations.

Key Dates

Dabur India has received an import alert from the US Food and Drug Administration (US FDA) pertaining to its manufacturing facility located in Silvassa. The regulatory action signals that products from the said plant may be subject to detention without physical examination upon entry into the United States market. The company has characterised the financial impact of this development as insignificant.

Regulatory Action Details

The US FDA import alert specifically targets Dabur India's Silvassa plant, placing the facility under heightened regulatory scrutiny. Import alerts issued by the US FDA are a formal mechanism through which the agency restricts or flags products from facilities found to be non-compliant with applicable US regulatory standards.

Company's Response

Dabur India has acknowledged the import alert and stated that the financial effect of this regulatory development on the company is expected to be insignificant. The company's position suggests that the Silvassa facility's contribution to its US-bound business is limited in scope relative to its overall operations.

Key Takeaways

• The US FDA has issued an import alert specifically for Dabur India's Silvassa manufacturing plant.
• Products from the affected facility may face detention at US ports of entry without physical examination.
• Dabur India has publicly stated that the financial impact of the alert will be insignificant.
• The development highlights ongoing regulatory compliance requirements for Indian manufacturers seeking access to the US market.

The import alert underscores the importance of maintaining stringent manufacturing and quality standards for companies with exposure to regulated markets such as the United States. Dabur India's assertion of an insignificant financial impact will be closely watched by investors and market participants as the situation develops.